This Master's programme trains experts in the entire drug development chain, from initial molecule discovery to regulatory approval. Located in a hub for pharmaceutical innovation, the University of Turku offers a unique opportunity to become a key contributor to the global pharmaceutical field. The curriculum provides a deep understanding of modern methods for identifying and validating drug targets, designing new drug modalities, and conducting clinical trials. Students will also gain knowledge in drug regulatory science, pharmacovigilance, and biostatistics, ensuring a strong foundation in both scientific and regulatory aspects. Graduates will be equipped to work in companies, research institutions, or regulatory authorities, with strong career prospects and potential for further academic study.
The programme provides comprehensive expertise across the entire drug development pipeline. Students will gain a deep understanding of up-to-date methods applied to identify and validate new drug targets, design novel drug modalities, and conduct clinical trials. They will also master knowledge of drug regulatory science, pharmacovigilance, and biostatistics.
Graduates will be well-prepared for research and development roles in both academia and industry. The programme's content is designed with working life in mind, equipping students with the skills to formulate and solve scientific problems, conduct independent research, critically review literature, and produce high-quality scientific texts. They will also be proficient in applying computational methods and working in global collaborative networks.
Applicants must have excellent English skills, proven by an internationally recognized test. No exceptions are made. The application is evaluated based on background studies, academic performance, relevant laboratory experience, motivation letter, and potentially a pre-assignment and interview for top candidates.
Tuition fees apply to non-EU/EEA citizens. The first year's tuition fee must be paid before registration. An Early Bird discount of 2,000 EUR is available if the study offer is accepted and the fee is paid within 28 days of admission decisions.
Non-EU/EEA citizens are subject to tuition fees of 12,000 EUR per year. Finnish/EU/EEA citizens are not required to pay tuition fees. The first year's tuition fee must be paid before registration.
Yes, an Early Bird discount of 2,000 EUR is available. To receive this discount, you must accept the study offer and pay the tuition fee within 28 days of the admission decision.
The programme has a duration of 24 months, which is equivalent to two years of study. The second year includes the Master's Thesis.
Applicants need a relevant Bachelor's degree (minimum 180 ECTS) in fields like biochemistry or pharmacology. You must also demonstrate excellent English proficiency with a minimum IELTS score of 6.0 overall.
Applications are submitted through the Studyinfo.fi portal during the application period. You will need to provide academic transcripts, degree certificates, proof of English proficiency, and a motivation letter.
Graduates can pursue roles such as Drug discovery researcher, Drug development specialist, or Regulatory affairs specialist in academia or industry. The programme prepares students for R&D positions.